CAR T-cell therapy in Shanghai Tongji Hospital, International Department
About the clinic
CAR T-cell therapy at the International Department of Shanghai Tongji Hospital in China is a specialized treatment for blood cancers. The hospital is a leading center for this method, focusing on patients with lymphoma, leukemia, and multiple myeloma. This facility is a university-affiliated hospital certified by the National Health Commission.
Experience and Success Rates
The medical team has performed 1,500+ CAR-T infusions since starting the program in 2014. This high volume makes it one of the most experienced centers for cell therapy globally. Patients with lymphoma have shown strong results at this facility. Data shows a complete remission rate of about 87.5% at the three-month mark for these cases. The hospital also publishes its research in major journals like Nature Cancer.
Standardized Treatment Pathway
The hospital follows a strict process to manage patient safety and cell quality. The treatment includes several specific stages:
- Patient selection using immunophenotyping to check eligibility.
- Cell preparation where the patient’s T-cells are modified in a lab.
- Bridging therapy to stabilize the patient before the infusion.
- Infusion of the modified cells back into the bloodstream.
- Long-term follow-up to monitor the patient's recovery.
Advanced Care and Research
A multidisciplinary tumor board manages every case. This team includes experts in hematology, radiology, and pathology. They also provide nutrition and psychological support during the hospital stay. For high-risk cases that do not respond to standard care, the hospital uses epigenetic immunotherapy. The center is also developing next-generation treatments, such as CAR-NK cell therapies, through active clinical trials.
Diagnostic Tools
Doctors use precise tools to plan the treatment and monitor its effects. These include biopsy and imaging-guided assessments to track the tumor's response. The team also uses detailed lab tests to make sure the patient is a good candidate for the therapy. This helps the medical staff choose the right strategy for refractory or relapsed cancers.
If you are looking for advanced cell therapy options, you can leave a request on Bookimed to receive more information about the program in Shanghai.
Highlights
Get a free consultation

Accepted payment methods
View more information
Treatments prices in the clinic
| diagnostics | Price | |
|---|---|---|
| Online Consultation with Hematologist | $500 |
| treatment | Price | |
|---|---|---|
| CAR-T for Pediatric ALL | $250000 - $280000 | |
| CAR-T for Multiple Myeloma | $250000 - $280000 | |
| CAR-T for DLBCL | $250000 - $280000 | |
| CAR T-cell therapy | Price on request | |
| Bone marrow transplantation | Price on request | |
| Chemotherapy | Price on request | |
| Leukemia chemotherapy | Price on request | |
| Lymphoma chemotherapy | Price on request |
Clinic Doctors
How are we doing?
Licences
Shanghai Tongji Hospital, International Department: more details about the clinic
Shanghai Tongji Hospital (Shanghai Tongji Hospital), affiliated with Tongji University, is a major public tertiary hospital in Shanghai and one of China’s leading centers for hematology and blood cancer treatment, including lymphoma, leukemia, and multiple myeloma. The Hematology Department and Blood-Tumor Clinical Research Center specialize in advanced cellular immunotherapy, including CAR-T and CAR-NK therapies.
The hospital established its CAR-T program in 2014 and has since performed more than 1,500 CAR-T cell infusions, making it one of the most experienced centers in this field. Over years of clinical development, the team has built a standardized treatment pathway covering patient selection, cell preparation, bridging therapy, infusion, and long-term follow-up. Reported outcomes include a 3-month complete remission rate of approximately 87.5% in lymphoma patients.
For high-risk and refractory cases, the hospital has developed combination approaches such as CAR-T based therapies integrated with additional treatment strategies, improving long-term remission outcomes in selected patient groups. The center has also contributed to the development of innovative approaches such as epigenetic immunotherapy for patients who have not responded to multiple prior treatments.
In lymphoma care, particularly diffuse large B-cell lymphoma (DLBCL), the hospital reports high clinical effectiveness, including strong remission rates in both newly diagnosed and relapsed or refractory cases, significantly improving outcomes compared to conventional therapies.
The hospital is actively involved in global research and clinical innovation, including publications on next-generation CAR-NK cell therapies in leading scientific journals such as Nature Cancer. Its research focuses on improving accessibility, durability, and safety of cellular immunotherapy.
Patient care is organized through a multidisciplinary tumor board involving hematology, radiology, pathology, imaging, nutrition, and psychological support specialists. Advanced diagnostic tools include immunophenotyping for CAR-T eligibility, biopsy techniques, and imaging-guided assessments to ensure precise treatment planning.
Shanghai Tongji Hospital is recognized for its extensive clinical experience in CAR-T therapy, participation in clinical trials, high remission outcomes in lymphoma treatment, and contribution to international research in cellular immunotherapy.
Additional services
Requirements for admission
Patient reviews
Wanyang Qiao
Chung Wah, John Chau
Maxim Beatty
Jay Chen
200 Renmin Ave, People's Square, Huang Pu Qu, Shang Hai Shi, China, 200003
Get a free consultation

How it works:
- We find a medical coordinator familiar with the matter
- You get a personal offer with a step-by-step guide and the cost estimate
- We arrange your travel including appointment scheduling and flights booking
- You arrive at the hospital, we support you 24/7

